Neurotrimin and Syndecan-1 Biomarker Levels in Patients With Decompensated Heart Failure

Heart failure (HF) is a complex clinical syndrome estimated to have afflicted 23 million people worldwide. This study aimed to measure syndecan-1 and neurotrimin levels in patients with decompensated heart failure (DHF) admitted to the emergency department.
 
This study was conducted from November 2017 through June 2018 in Imam Khomeini Hospital, a referral center in Ahvaz, Iran. Baseline demographics were recorded. The Human Syndecan-1/CD138 (SDC1) ELISA kit for the measurement of syndecan 1 and the Human Neurotrimin ELISA kit for the measurement of neurotrimin (ZellBio GmbH, Berlin, Germany) were used. The detection range for syndecan 1 and neurotrimin was 1.5 to 48 ng/mL and 0.4 to 12.8 ng/mL, respectively.
 
Seventy-two patients met the study inclusion criteria. The mean level of syndecan 1 and neurotrimin was 24.31 ± 8.27 ng/mL (11–37 ng/mL) and 0.52 ± 0.19 ng/mL (0–9 ng/mL), respectively. The results showed no correlations between the severity of illness and syndecan-1 and neurotrimin levels, nor were there any correlations between age, sex, blood urea nitrogen, creatinine, the estimated glomerular filtration rate, and B-type natriuretic peptide (in DHF >500 ng/mL) and the levels of syndecan 1 and neurotrimin (P >0.05).
 
The syndecan-1 level did not change in patients suffering from HF with reduced ejection fraction (EF). Further, patients in any EF classification had a low level of neurotrimin. However, no significant associations were found between the classes of the EF and the serum neurotrimin level. (Iranian Heart Journal 2021; 22(3): 88-94)